Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13721
Abstract: Evidence on the carcinogenicity of oral nucleos(t)ide analogues (NAs) is inconclusive and lacks data on the effects by chemical structure of the NAs in patients with chronic hepatitis B (CHB). We aimed to provide definitive… read more here.
Keywords: nucleos ide; carcinogenicity oral; ide analogues; chronic hepatitis ... See more keywords
Safety Considerations for Withdrawal of Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B: First, Do No Harm.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and molecular hepatology"
DOI: 10.3350/cmh.2022.0420
Abstract: Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis… read more here.
Keywords: safety; nucleos ide; ide analogues; hepatitis ... See more keywords